Literature DB >> 2787951

Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2.

T Ishikawa1, T Ikawa, M Eura, T Fukiage, K Masuyama.   

Abstract

Peripheral blood lymphocytes drawn by leukapheresis using Haemonetics V50 were mixed and cultured with autologous or allogeneic tumour cell line to activate killer cells by tumour antigenic stimulation, and further with recombinant interleukin-2 (rIL-2). Killer cells were intra-arterially infused, as a primary therapy, in 5 patients with maxillary and one with lingual cancer (squamous cell carcinoma). Effects on reduction of primary tumour size were significantly high without any severe side effects. The effects were interpreted mainly by direct day-by-day observation of the site, findings of CT and histology. Histological findings of the tissue obtained by surgical operation performed after adoptive immunotherapy were remarkable changes, such as infiltration of lymphoid cells around the cancer nets, degeneration of cancer cells, infiltration of scavenger macrophages (giant cells) and so on. The results suggested that adoptive immunotherapy by the killer cells can be a powerful treatment to bring the cancer under control, in with combination of other therapies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787951     DOI: 10.3109/00016488909127519

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

Review 3.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

Review 4.  Interferons and other cytokines in head and neck cancer.

Authors:  V K Hamasaki; E E Vokes
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

5.  Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells.

Authors:  Yasunori Akutsu; Toshinori Nakayama; Michishige Harada; Tetsu Kawano; Shinichiro Motohashi; Eiko Shimizu; Toshihiro Ito; Noriaki Kamada; Takeshi Saito; Hisahiro Matsubara; Yukimasa Miyazawa; Takenori Ochiai; Masaru Taniguchi
Journal:  Jpn J Cancer Res       Date:  2002-04

6.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

7.  Characterization of transendothelial migratory lymphokine-activated killer cells.

Authors:  K Nakano; M Eura; K Chikamatsu; K Masuyama; T Ishikawa
Journal:  Jpn J Cancer Res       Date:  1996-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.